Do findings from new trials for schizophrenia fit with existing evidence: Not duped... just beguiled?

Epidemiologia e Psichiatria Sociale

Volumn 16, Issue 3, 2007, Pages 199-202

  Adams, Clive E ^a   Jayaram, Mahesh ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE;

BLOOD DYSCRASIA; CLINICAL TRIAL; DELUSION; DRUG INDUSTRY; DRUG RESEARCH; HALLUCINATION; HUMAN; LONG TERM CARE; REVIEW; SCHIZOPHRENIA;

EID: 34447539907     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1121189x00002281     Document Type: Review

References (32)

1. Adams C.E. (2002). Schizophrenia trials: past, present and future. Epidemiologia e Psichiatria Sociale 11, 144-1451.
2. Adams C.E., Tharyan P., Coutinho E.S. & Stroup T.S. (2006). The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. British Journal of Psychiatry 189, 391-392.
3. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., Pitkin R., Rennie D., Schulz K.F., Simel D. & Stroup D.F. (1996). Improving the quality of reporting of randomized controlled trials. The CONSORT statement. Journal of American Medical Association 276, 637-639.
4. Centre for Reviews and Dissemination (2007). Drug treatments for schizophrenia - Effective Health Care Bulletin. Retrieved June 4, 2007, from http://www.york.ac.uk/inst/crd/ehc56.htm
5. Duggan L., Fenton M., Dardennes R.M., El-Dosoky A. & Indran S. (2000). Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
6. Duggan L., Fenton M., Rathbone J., Dardennes R., El-Dosoky A. & Indran S. (2005). Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
7. Dyer O. (2007). Lilly investigated in US over the marketing of olanzapine. British Medical Journal 334, 171.
8. El-Sayeh H.G. & .Morganti C. (2006). Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
9. Freeman H. (1958). The tranquilising drugs. In Schizophrenia: A Review of the Syndrome (ed. L. Bellak). Logos Press: New York.
10. Hafner H. (2004). Schizophrenia: still Kraepelin's dementia praecox? Epidemiologia e Psichiatria Sociale 13, 99-112.
11. Härtung B., Wada M., Laux G. & Leucht S. (2005). Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 1.
12. Heres S., Davis J., Maino K., Jetzinger .E, Kissling W. & Leucht S. (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163, 185-194.
13. Hotopf M., Churchill R. & Lewis G. (1999). Pragmatic randomised controlled trials in psychiatry. British Journal of Psychiatry 175, 217-223.
14. Jayaram M.B., Hosalli P. & Stroup S. (2006). Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
15. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A. & Lewis S.W. (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63, 1079-12087.
16. Joy C.B., Adams C.E. & Lawrie S.M. (2006). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4.
17. Kane J., Honigfeld G., Singer J. & Meltzer H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
18. Kennedy E., Song F., Hunter R., Clarke A. & Gilbody S. (2000). Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
19. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. & Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
20. Marques L.O., Lima M.S. & Soares B.G. (2004). Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 1.
21. Matar H. &.Almerie M. (2007). Oral fluphenazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 1.
22. Montgomery J.H., Byerly M., Carmody T., Li B., Miller D.R., Varghese F. & Holland R. (2004). An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials 25, 598-612.
23. Mota N.E., Lima M.S. & Soares B.G. (2002). Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
24. NHS National Institute for Clinical Excellence (2007). Schizophrenia: NICE guideline. Retrieved June 4, 2007, from http://www.nice.org.uk/guidance/ CG1/niceguidance/pdf/English
25. Soares B.G., Fenton M. & Chue P. (2000). Sulpiride for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
26. Srisurapanont M., Maneeton B. & Maneeton N. (2004). Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
27. Thornley B. & Adams C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317, 1181-1184.
28. Thornley B., Rathbone J., Adams C.E. & Awad G. (2003). Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
29. Turner T. (2007). Chlorpromazine: unlocking psychosis. British Medical Journal 334, Suppl 1, s7.
30. Tuunainen A., Wahlbeck K. & Gilbody S.M. (2000). Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.
31. Vedantam S. (2006). In antipsychotics, newer isn't better - drug find shocks researchers. Washington Post, Tuesday, October 3, 2006. Retrieved June 4, 2007, from http://www.washingtonpost.com/wp-dyn/content/article/2006/10/ 02/AR2006100201378.html
32. Wahlbeck K., Cheine M. & Essali M.A. (2000). Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.